InMed completes Mentari merger, shares to trade as MTRI
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
InMed Pharmaceuticals has completed its merger with privately held Mentari Therapeutics, with the combined company renamed Mentari Therapeutics, Inc. and shares expected to trade on Nasdaq as MTRI from November 9, 2026. Mentari previously raised roughly $490 million in private financings, including conversion of $50 million in convertible notes.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.